FOI release

NCT06054425 – Clinical Study Report and Trial Information

Some or all of the information requested was not provided because we didn't hold it.

Case reference FOI2026/00429

Received 21 April 2026

Published 27 October 2026

Request

Dear FOI team, Thank you for your letter of 27 March 2026. I appreciate the consideration of my request dated 27 February 2026 (Your Ref: FOI2026/00211). I note the Agency is treating this request as vexatious because of the burden that would be placed on MHRA and its staff in retrieving the entire records for each of the 8 studies in total. I would therefore like to reduce the scope of my request to information on the single specific study, NCT06054425 (“A Study to Compare the Bioavailability of Intravenously Infused Risankizumab Manufactured by Two Different Processes in Healthy Adults”). In addition, I would like to request the clinical study report relating to the outcome of this specific clinical trial. Should any part of the requested information be exempt from disclosure, I kindly ask that you provide the non-exempt portions.

Response

See attached

Documents

• FOI2026_00429 (redacted).pdf (499.4 KB)

This is Medicines and Healthcare products Regulatory Agency's response to a freedom of information (FOI) or environmental information regulations (EIR) request.

You can browse our other responses or make a new FOI request.